Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01302119 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of AN2690 Topical Solution to Treat Onychomycosis of the Toenail
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 604
- Enrollment target
NCT01302119 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 604 participants.
The verdict
NCT01302119, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 604 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether AN2690 topical solution is a safe and effective treatment for onychomycosis of the toenail.
Interventions
- DRUG AN2690 Topical Solution, 5%
- DRUG Solution Vehicle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 604 participants |
| Start Date | 2011-02 |
| Est. Completion | 2013-02-20 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01302119
The ClinicalTrials.gov registry entry for NCT01302119 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 604 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which AN2690 Topical Solution, 5% is the first listed.
NCT01302119 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01302119 about?
NCT01302119 is a clinical study titled "Efficacy and Safety of AN2690 Topical Solution to Treat Onychomycosis of the Toenail". The purpose of this study is to determine whether AN2690 topical solution is a safe and effective treatment for onychomycosis of the toenail.
What is the current status of trial NCT01302119?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 604 participants. The study started on 2011-02. Estimated completion is 2013-02-20.
What interventions are being tested in trial NCT01302119?
The interventions under investigation include: AN2690 Topical Solution, 5% (DRUG), Solution Vehicle (DRUG).
Who is sponsoring clinical trial NCT01302119?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.